In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Documenti analoghi

• Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
  di: Teng, R, et al.
  Pubblicazione: (1996)
• Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
  di: Wise, R, et al.
  Pubblicazione: (1996)
• Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
  di: Gootz, T D, et al.
  Pubblicazione: (1996)
• Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
  di: Kenny, G E, et al.
  Pubblicazione: (1996)
• Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.
  di: Hook, E W, et al.
  Pubblicazione: (1996)